High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

Manuela Gambella, Alberto Rocci, Roberto Passera, Francesca Gay, Paola Omedè, Claudia Crippa, Paolo Corradini, Alessandra Romano, Davide Rossi, Marco Ladetto, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticle

Original languageEnglish
JournalHaematologica
Volume99
Issue number2
DOIs
Publication statusPublished - Feb 1 2014

Keywords

  • BLIMP1
  • Bortezomib
  • IRF4
  • Multiple myeloma biomarker
  • XBP1

ASJC Scopus subject areas

  • Hematology

Cite this